Javlor Falls Short Again At NICE; Even Sole Treatment In Class Faces Cost Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE questions the cost and clinical effectiveness Pierre Fabre’s Javlor for metastatic transitional cell carcinoma in a disappointing final appraisal for the drug.
You may also be interested in...
NICE Rejects Pierre Fabre’s Javlor, Citing Basic Evidence Errors
Britain’s NICE has turned down Pierre Fabre’s Javlor for cancer of the urothelial tract, saying the French company’s basic trial structure did not meet its requirements.
NICE Proves Cost Is Not Everything, Clears Two High-Priced Skin Cancer Drugs
Roche’s Zelboraf and Bristol-Myers Squibb’s Yervoy exceed NICE’s cost-effectiveness limit, but are still waved through as targeting unmet medical need.
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
The British drug costs regulator turns down Roche's Tarceva, Pierre Fabre's Javlor and PharmaMar's Yondelis for use in the NHS in certain indications.